Followers | 5 |
Posts | 973 |
Boards Moderated | 0 |
Alias Born | 03/03/2011 |
Sunday, June 26, 2011 10:50:58 AM
cwheeler@momentapharma.com, rshea@momentapharma.com, bholley@momentapharma.com
As a shareholder, I would request you to send emails to the management asking them details on transparency on their FOB development(both number of drugs, type of biologics, timelines) without of-course disclosing anything that would jeopardize their IP or help competition. Also I would ask them on some sort of timelines on the 2 new drugs. I just happened to listened to Q2 call of 2010. heard the same generic talk from cw then ( a year back). Ask him more line item details on 60m-80m spend
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM